October 22nd, 2007. (Press Release) Statement by Daniel Schultz, M.D., director of the Center for Devices and Radiological Health: Medtronic's decision to voluntarily remove its Sprint Fidelis defibrillation leads from the market is in the best interest of patient safety. These electronic wires are prone to fracture in a small number of patients which ... [More >>]
October 19th, 2007. (Press Release) On Monday, October 15, Medtronic, Inc. said voluntarily suspended worldwide distribution of the Sprint Fidelis® family of defibrillation leads because of the potential for lead fractures. In addition, the company recommends against new implants of the leads (Sprint Fidelis Models: 6930, 6931, 6948, 6949). The Sprint ... [More >>]
July 17th, 2007. A new study published in the Annals of Internal Medicine finds that most type-2 diabetics are better off using older, cheaper diabetes drugs than their heavily advertised, newer counterparts. With the exception of those who cannot tolerate specific drugs like Glucophage (metformin), the effectiveness of the older medications was on ... [More >>]
June 29th, 2007. One million type two diabetics in the US, and nearly 6 million worldwide, who take Avandia (rosiglitazone maleate) may be putting themselves at an increased risk of heart attack. Earlier this spring, The New England Journal of Medicine released a study by Dr. Steven Nissen that analyzed the combined results ... [More >>]
May 21st, 2007. (Press Release) The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths ... [More >>]
March 15th, 2007. Drugs included in the label warning update are the following 13 products: Ambien/Ambien CR (Sanofi Aventis) Butisol Sodium (Medpointe Pharm HLC) Carbrital (Parke-Davis) Dalmane (Valeant Pharm) Doral ... [More >>]
March 14th, 2007. (Press Release) The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks. These risks include severe allergic reactions and complex sleep-related behaviors, which may include ... [More >>]
July 28th, 2006. Injured by Zyprexa? Side effects of this antipsychotic drug include diabetes, weight gain, hyperglycemia, pancreatitis, and diabetic ketoacidosis. Zyprexa Risks The following are the risks and side effects associated with Zyprexa therapy. This list is not exhaustive. From the FDA web site, Zyprexa's risks include: A life-threatening nervous system ... [More >>]
May 18th, 2006. 5/5/06 - FDA Updates Regarding Voluntary Market Withdrawal of Bausch & Lomb ReNu MoistureLoc® Contact Lens Solution 4/13/06 - Bausch & Lomb Asks Retailers to Remove U.S.-Manufactured ReNu® with MoistureLoc® from Shelves; and Recommends Consumers Switch to Another Solution Pending Investigation of Reports of Fusarium Infections Among ... [More >>]
May 8th, 2006. With Bush Republicans in the Senate seeking to use their "health" week to push Medical Malpractice legislation that will do nothing to fix the health care crisis in America today, Senate Democratic Leader Harry Reid delivered the following remarks on the Floor of the U.S. Senate. The text of Senator Reid's ... [More >>]
